65 results on '"Matsuda, Kuniko"'
Search Results
2. Phosphoproteomic analysis identified mutual phosphorylation of FAK and Src as a mechanism of osimertinib resistance in EGFR-mutant lung cancer
3. Increased CTGF expression in alveolar epithelial cells by cyclic mechanical stretch: its mechanism and the therapeutic effect of pirfenidone
4. Data from MiR-134/487b/655 Cluster Regulates TGF-β–Induced Epithelial–Mesenchymal Transition and Drug Resistance to Gefitinib by Targeting MAGI2 in Lung Adenocarcinoma Cells
5. Data from MiR-134/487b/655 Cluster Regulates TGF-β–Induced Epithelial–Mesenchymal Transition and Drug Resistance to Gefitinib by Targeting MAGI2 in Lung Adenocarcinoma Cells
6. Supplementary Figure 2 from MiR-134/487b/655 Cluster Regulates TGF-β–Induced Epithelial–Mesenchymal Transition and Drug Resistance to Gefitinib by Targeting MAGI2 in Lung Adenocarcinoma Cells
7. Supplementary Figure 1 from MiR-134/487b/655 Cluster Regulates TGF-β–Induced Epithelial–Mesenchymal Transition and Drug Resistance to Gefitinib by Targeting MAGI2 in Lung Adenocarcinoma Cells
8. Supplementary Figure 2 from MiR-134/487b/655 Cluster Regulates TGF-β–Induced Epithelial–Mesenchymal Transition and Drug Resistance to Gefitinib by Targeting MAGI2 in Lung Adenocarcinoma Cells
9. Supplementary Figure 1 from MiR-134/487b/655 Cluster Regulates TGF-β–Induced Epithelial–Mesenchymal Transition and Drug Resistance to Gefitinib by Targeting MAGI2 in Lung Adenocarcinoma Cells
10. Supplementary Fig. S1 from Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model
11. Supplementary Fig. S2 from Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model
12. Supplementary Fig. S2 from Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model
13. Supplementary Fig. S1 from Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model
14. Serum-derived exosomal miR-125a-3p predicts the response to anti-programmed cell death-1/programmed cell death-ligand 1 monotherapy in patients with non-small cell lung cancer
15. Increased Ctgf Expression in Alveolar Epithelial Cells by Cyclic Mechanical Stretch: Its Mechanism and the Therapeutic Effect of Pirfenidone
16. MO20-6 CADM1 and SPC25 gene mutations in lung cancer patients with idiopathic pulmonary fibrosis
17. Inhibitors of ABCB1 and ABCG2 overcame resistance to topoisomerase inhibitors in small cell lung cancer
18. The respiratory microbiome associated with chronic obstructive pulmonary disease comorbidity in non‐small cell lung cancer
19. A Novel Molecular Target in EGFR-mutant Lung Cancer Treated With the Combination of Osimertinib and Pemetrexed
20. CADM1 and SPC25 Gene Mutations in Lung Cancer Patients With Idiopathic Pulmonary Fibrosis
21. Exosome‐derived miR ‐210 involved in resistance to osimertinib and epithelial–mesenchymal transition inEGFRmutant non‐small cell lung cancer cells
22. PD-L1 Expression Status Predicting Survival in Pulmonary Pleomorphic Carcinoma
23. Long Non-Coding RNA CRNDE Is Involved in Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant Lung Cancer via eIF4A3/MUC1/EGFR Signaling
24. A Novel Molecular Target in EGFR-Mutant Non-Small Cell Lung Cancer Treated With a Combination of Osimertinib and Pemetrexed
25. Long Non-Coding RNA CRNDE is Involved in Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant Lung Cancer via eIF4A3/MUC1/EGFR Signaling
26. Rictor-targeting exosomal microRNA-16 ameliorates lung fibrosis by inhibiting the mTORC2-SPARC axis
27. Abstract 3068: The glycoprotein inhibitors overcome the resistance of the topoisomerase inhibitors in small cell lung cancer
28. Exosome-Derived microRNA-22 Ameliorates Pulmonary Fibrosis by Regulating Fibroblast-to-Myofibroblast Differentiation in Vitro and in Vivo
29. Abstract 1602: Genomic profiling of lung cancer associated with idiopathic pulmonary fibrosis
30. Abstract 1602: Genomic profiling of lung cancer associated with idiopathic pulmonary fibrosis
31. Resolution of bleomycin-induced murine pulmonary fibrosis via a splenic lymphocyte subpopulation
32. Synergistic effect of targeting dishevelled‑3 and the epidermal growth factor receptor‑tyrosine kinase inhibitor on mesothelioma cells in vitro
33. XPLN is modulated by HDAC inhibitors and negatively regulates SPARC expression by targeting mTORC2 in human lung fibroblasts
34. Pirfenidone exerts a suppressive effect on CCL18 expression in U937-derived macrophages partly by inhibiting STAT6 phosphorylation
35. Nintedanib modulates surfactant protein-D expression in A549 human lung epithelial cells via the c-Jun N-terminal kinase-activator protein-1 pathway
36. MET FISH-positive status predicts short progression-free survival and overall survival after gefitinib treatment in lung adenocarcinoma with EGFR mutation
37. Pirfenidone inhibits fibrocyte accumulation in the lungs in bleomycin-induced murine pulmonary fibrosis
38. MiR-134/487b/655 Cluster Regulates TGF-β–Induced Epithelial–Mesenchymal Transition and Drug Resistance to Gefitinib by Targeting MAGI2 in Lung Adenocarcinoma Cells
39. A non-HIV case with disseminated Mycobacterium kansasii disease associated with strong neutralizing autoantibody to interferon-γ
40. Abstract 5548: High copy number of the MET gene predicts resistance to EGFR-TKI in non-small cell lung cancer patients.
41. Sequential Analysis of Myofibroblast Differentiation and Transforming Growth Factor-β1/Smad Pathway Activation in Murine Pulmonary Fibrosis
42. N-Acetylcysteine And Pirfenidone Attenuate Expression Of Epithelial Mesenchymal Transition In Murine Bleomycin-Induced Pulmonary Fibrosis
43. Reduction in Serum High Mobility Group Box-1 Level by Polymyxin B-Immobilized Fiber Column in Patients with Idiopathic Pulmonary Fibrosis with Acute Exacerbation
44. HSP27 modulates epithelial to mesenchymal transition of lung cancer cells in a Smad-independent manner
45. Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU/S-1 via down-regulation of thymidylate synthase expression and up-regulation of p21waf1/cip1 expression
46. Anticancer drug clustering based on proteomic profiles and a sensitivity database in a lung cancer cell line panel
47. Neutrophil Adsorption by Polymyxin B-Immobilized Fiber Column for Acute Exacerbation in Patients with Interstitial Pneumonia: A Pilot Study
48. The Anticancer Effect of Histone Deacetylase Inhibitors and Combination with the Cytotoxic Agents in Lung Cancer Cells: Biological Analyses for Future Clinical Application
49. Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model
50. EM703, A NEW DERIVATIVE OF ERYTHROMYCIN, INHIBITS TRANSFORMING GRWTH FACTOR-β SIGNALING IN HUMAN LUNG FIBROBLASTS
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.